Physician profile
Mariah Barstow Piazza
NPI 1578023297
$865.24
in general payments reported to CMS, 2019-2025
14 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $159 · 2024: $401 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $203.66 | 2024-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $148.86 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $65.22 | 2023-2025 | |
| Amgen INC. | $59.18 | 2023-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $56.15 | 2023-2024 | Rexulti |
| Sage Therapeutics, LLC | $52.51 | 2024-2025 | Zurzuvae |
| Exact Sciences Corporation | $51.40 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Exeltis, USA INC. | $50.84 | 2024-2025 | Slynd |
| Mayne Pharma Commercial LLC | $43.16 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $38.39 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $33.09 | 2024-2025 | Mounjaro, Zepbound |
| Gebauer Company | $29.43 | 2025 | |
| Dexcom, INC. | $19.73 | 2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $13.62 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariah Piazza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.